ICYMI: Eli Lilly's New Weight Loss Pill

Up next

White House Pushes to Unlock Nuclear Energy with 'UPRISE'

The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF. Ho K. Nieh, chairman of the Nuclear Regulatory Commission joins following the UPRISE (Utility Power Reactor Incremental Scaling Effort) event at the ... Show more

. 8min 2sec

Fed Edges Closer to Rate Hikes in Kevin Warsh's First Fed Meeting

The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF. Federal Reserve Chairman Kevin Warsh vowed to restore price stability following his first policy meeting since taking the helm of the US central bank ... Show more

. 35min 8sec

Recommended Episodes

Market Rally Aims for “Cloud Nine,” Bronfman's Paramount Bid, Eli Lilly CEO on Weight-Loss Drug 8/20/24

Squawk on the Street

Carl Quintanilla and Jim Cramer led off the show by delving into the broadening market rally, as the S&P 500 and Nasdaq aim for a ninth consecutive day of gains. David Faber called into the show with reporting on Edgar Bronfman's bid to acquire Paramount Global. Eli Lilly CEO ...

. 44min 46sec

Deep Dive: Novo Nordisk & Eli Lilly Stumble Into Next Phase of Ozempic Era

The Rundown

Two pharma giants, Eli Lilly and Novo Nordisk, are in a high-stakes race for leadership in the $150 billion GLP-1 obesity drug market. We examine Lilly’s latest earnings, the mixed results from its oral pill orforglipron, and Novo’s push with higher-dose oral semaglutide. We also ... Show more

. 11min 3sec

More Big Tech Results… And Dissecting The Latest Pharma Moves 10/30/25

CNBC's "Fast Money"

Apple & Amazon the latest big tech names to report results. The headlines from the company conference calls, and what top tech analyst Gene Munster sees in store for the group. Plus Eli Lilly jumping as its obesity drug sales soar. How the company is moving the needle in the w ...

. 43min 58sec

Big Tech Reports… And Eli Lilly’s Letdown 10/30/24

CNBC's "Fast Money"

Meta and Microsoft in focus, as the big tech names report results. How our traders are handling the moves, and what it means for entire tech trade. Plus Eli Lilly getting hit, as the pharma stock misses estimates and slashes guidance. So are the disappointing results a sign th ...

. 43min 47sec